Fluoxetine-citalopram

From Psychiatrienet
Revision as of 10:10, 28 October 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine
Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram

Switch medication from fluoxetine to citalopram.[1] [2]

Nietinrijdenbord.png Stop fluoxetine

Template:StopFluoxetin

  • Gradually reduce dosage of fluoxetine to a maximum of 20 mg/ day, when this dosage is > 20 mg/day.
  • When a dosage of 20 mg/day is reached, stop administration.
Eenrichtingbord.png Start citalopram
  • No wash-out period is needed.
  • Day 1: start citalopram the next day in low dosage of 10 mg/day.
  • Day 14: increase dosage of citalopram to normal, i.e. 20 mg/day.
Infobord.png More information
  • Fluoxetine has a very long elimination time; phasing out fluoxetine is therefore not necessary.
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluoxetine inhibits CYP2C19, CYP2D6 and CYP3A4, which metabolize citalopram.
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.